Regencor

Executive Summary

Regencor is a preclinical-stage regenerative medicine company developing REG101, a first-in-class recombinant protein therapeutic designed to repair cardiac tissue and restore function after myocardial infarction. The company's innovative approach uses a simple, non-invasive subcutaneous delivery method to stimulate heart muscle regeneration, addressing a significant unmet need in cardiovascular disease. Founded in 2018 and based in San Diego, Regencor is privately held and has not yet disclosed funding or valuation. The preclinical data support the potential of REG101 to improve outcomes for the millions of patients who suffer heart attacks annually, though the company has not yet initiated clinical trials. The cardiac repair market is large and growing, with limited approved regenerative therapies. REG101's unique mechanism and non-invasive delivery could differentiate it from cell-based or gene therapies. However, as a preclinical asset, Regencor faces substantial risks including regulatory hurdles, manufacturing scalability, and competition from other early-stage approaches. The company's near-term success hinges on successful IND-enabling studies and securing funding or partnerships to advance into the clinic. If REG101 demonstrates safety and efficacy in humans, it could become a transformative therapy for post-MI patients, but significant execution and capital risks remain.

Upcoming Catalysts (preview)

• Q4 2026IND submission for REG10160% success
• Q3 2026Series A or partnership financing announcement50% success
• Q2 2026Publication of preclinical efficacy data in peer-reviewed journal70% success